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Abstract
Background: Previous studies have established that levels of the Inhibitor of Growth 1(ING1) tumor suppressor
are reduced in a significant proportion of different cancer types. Here we analyzed levels of ING1 in breast cancer
patients to determine its prognostic significance as a biomarker for breast cancer prognosis.
Methods: We used automated quantitative analysis (AQUA) to determine the levels of ING1 in the tumor
associated stromal cells of 462 breast cancer samples. To better understand how high ING1 levels affect nearby
epithelium, we measured the levels of cytokines and secreted matrix metalloproteases (MMPs), using an ELISA
based assay in mammary fibroblasts overexpressing ING1. These cells were also used in a 3-dimensional co-culture
with MCF7 cells to determine the effect of released MMPs and other cytokines on growing colonies.
Results: We find that high levels of ING1 in stroma are associated with tumor grade (p = 0.001) and size (p = 0.02),
and inversely associated with patient survival (p = 0.0001) in luminal, but not in non-luminal cancers, suggesting
that high stromal ING1 promotes cancer development. In this group of patients ING1 could also predict patient
survival and act as a biomarker (HR = 2.125). While ING1 increased or decreased the expression of different
cytokines, ING1 also increased the levels of MMP1, MMP3 and MMP10 by 5–8 fold, and concomitantly decreased
levels of the tissue inhibitors of metalloproteases TIMP2, TIMP3 and TIMP4 by 1.5–3.3 fold, resulting in significant
increases in MMP activity as determined by zymography. Co-culturing of MCF7 cells with stromal cells expressing
ING1 in 3-dimensional organoid cultures suggested that MCF7 colonies were less well defined, suggesting that
secreted MMPs might promote migration.
Conclusion: These data indicate that stromal ING1 expression can predict the survival of patients with luminal
breast cancer. High levels of ING1 in stromal cells can promote the development of breast cancer through
increased expression and release of MMPs and down regulation of TIMPs, which may be an underlying mechanism
of reduced patient survival.
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Background
Progression of tumors towards a malignant phenotype is
not exclusively dependent on the autonomous properties
of cancer cells, but is also influenced by the surrounding
stroma. Tumor microenvironment which includes the
extracellular matrix, surrounding blood vessels, endothelial
cells, cancer-associated fibroblasts (CAFs), macrophages
and other inflammatory cells, plays an important role in
cancer progression. As a cancer progresses, its surrounding
microenvironment co-evolves with it and attains an acti-
vated state through continuous paracrine communication,
which creates a dynamic signaling interaction that pro-
motes cancer initiation and growth [1].
The most prominent cell types in the tumor stroma
are the cancer-associated fibroblasts. CAFs are heteroge-
neous populations and their relative composition differs
among different tumor types [2]. The mechanisms that
* Correspondence: karl@ucalgary.ca
1Department of Biochemistry and Molecular Biology, University of Calgary,
3330 Hospital Drive, Calgary T2N 4N1, AB, Canada
5Department of Oncology, University of Calgary, 311 HMRB, 3330 Hospital
Drive, NW, Calgary T2N 4N1, AB, Canada
Full list of author information is available at the end of the article
© 2015 Thakur et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Thakur et al. Molecular Cancer  (2015) 14:164 
DOI 10.1186/s12943-015-0434-x
can activate CAFs in the stroma are still not clearly
understood but it is believed that tumor released factors
such as tumor growth factor beta (TGF-β), platelet
derived growth factor α/β (PDGFA, PDGFB), fibroblast
growth factor (FGF) and interleukin-6 (IL-6) play major
roles in trans-differentiation and activation of CAFs
[3–6]. Activated CAFs are known to contribute to tumor
progression by various cellular mechanisms. These cells
produce and release several hormones and cytokines such
as epidermal growth factors, fibroblast growth factors, IL-
6 etc., that can stimulate cancer cells to proliferate rapidly
[7]. While CAFs are well characterized for supporting
tumor progression, a few studies have also reported their
cancer-initiating capacity [8]. In addition to providing
growth cues to cancer cells, CAFs also contribute in evad-
ing apoptosis by constantly providing them with survival
signals like cytokines and insulin like growth factor (IGF)
[9]. They are also known to produce various matrix com-
ponents like collagen, which makes the extracellular mem-
brane (ECM) more cross-linked and has been shown to
enhance integrin signaling in cancer cells, which in turn
can activate pro-survival PI3K/AKT pathways downstream
[10]. CAF secreted cytokines and chemokines also lead to
the infiltration of various pro-inflammatory immune cells,
which can promote angiogenesis and metastasis [11].
Particularly, CAF released factors such as stromal derived
factor-1 (SDF-1), vascular endothelial growth factor
(VEGF), IL-8, IL-6, and IL-1β cooperate and promote new
vessel formation by recruiting endothelial cells [12].
CAFs also secrete several members of the matrix
metalloproteases (MMP) family. These enzymes can
degrade ECM, which helps tumor cells invade the sur-
rounding tissues. MMPs can also cleave membrane
bound growth factors like VEGF and cytokines as well
as their receptors and cell adhesion molecules like cad-
herins, which can lead to increased motility and result
in epithelial to mesenchymal transition (EMT) [13, 14].
As stroma derived factors promote initiation, growth
and progression of tumor cells, they can also determine
the therapeutic outcome in patients as they can act as
barriers to therapy [15].
Senescence can also affect tissue microenvironment
reactivity as well as secreted factors from CAFs. Senescent
fibroblasts acquire a senescence-associated secretory
phenotype (SASP) which turns senescent fibroblasts into
pro-inflammatory cells allowing them to increase their
pro-inflammatory and pro-angiogenic cytokine and che-
mokine production. SASP induction in stromal fibroblasts
has been positively correlated with tumor progression and
it has been observed that they show this effect by inducing
EMT in nearby epithelial cells [16]. Along with various
cytokines, senescent cells also secrete increased levels of
some MMPs. The MMP family members that are consist-
ently upregulated in senescent fibroblasts are MMP-1,
MMP-3 and MMP-10 [17]. These increased levels of
secreted MMPs can degrade the components of the extra-
cellular matrix, which can affect the physical property of
the tissue structure. This could help tumor cells migrate
and invade through the ECM. It has also been observed
that senescent cells and malignant tumors share many
common repertoires of MMPs indicating the significance
of senescence induction in tumor cell metastasis.
All ING family members (ING1-5) have been reported
to be altered in localization, sequence, or expression level
in various cancer types and are classified as type-II tumor
suppressors [18]. The human ING1 gene encodes four dif-
ferent isoforms, p47ING1a, p33ING1b, p24ING1c, and
p27ING1d, among which p47ING1a and p33ING1b are
the best characterized so far [19, 20]. ING gene products
possess distinct, but in some cases overlapping functional
properties and unique expression profiles in eukaryotic
systems [18, 21]. Ectopic overexpression of ING1 has been
found to block cell cycle progression by arresting cells in
G1 phase of the cell cycle, and long term expression pro-
motes apoptosis. Particularly, overexpression of p47ING1a
is known to induce senescence like characteristics includ-
ing high SA-β-gal activity, presence of SAHF, altered nu-
clear morphology, increased expression of p16 and Rb and
growth arrest [22], whereas, p33ING1b overexpression
induces cells to undergo apoptosis [23]. Consistent with a
role as a tumor suppressor, inhibition of ING1 expression
with antisense RNA promotes focus formation in vitro
and tumor formation in vivo [24, 25]. Loss of ING1
expression has been implicated in a broad range of human
cancer types, including primary breast tumors, lymphoid
malignancies, testis tumors, squamous cell cancers, and
head and neck cancers [18, 26–28]. Other members of the
ING family, and in particular ING4, have also been
reported to be down-regulated in breast cancers with a
dominant mutant allele of the ING4 gene promoting
tumor growth [29, 30]. Recently, we reported that reduced
ING1 levels are correlated with increased metastasis in
breast cancer patients [31].
Here we asked if ING1 expression could predict breast
cancer patient outcome using an automated quantitative
immune-histological technique to determine ING1 ex-
pression in the tumoral and stromal compartments of
patient tissue samples. We found that stromal expres-
sion of ING1 showed an inverse correlation with patient
survival. ING1 expression also correlated with tumor
grade in these patients and multivariate analysis showed
that ING1 was an independent prognostic marker in the
breast cancer cohort we tested. Furthermore, we found
that ING1 expression can regulate the levels of various
cytokines, matrix metalloproteases and their inhibitors,
tissue-inhibitors of matrix metalloproteases in mammary
fibroblasts that could explain partly, at least, the inverse
correlation between the stromal ING1 expression and
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patient survival. Overall, this study provides important
pre-clinical data that could help establish ING1 as a
prognostic and therapeutic agent for breast cancer.
Results
Stromal ING1 expression in breast cancer patient samples
ING1 protein level was measured using quantitative
fluorescence immunohistochemistry on the HistoRx
AQUA® platform in breast cancer patient samples from
the Calgary Tamoxifen cohort as described previously
[31]. The specificity of the ING1 monoclonal antibody
used for fluorescence IHC was assessed in HEK293 cells
and placental tissue Fig. 1a (top panel). The patient sam-
ples were also stained with anti-pan cytokeratin and
anti-vimentin antibodies to specifically demarcate the
tumor region from the stromal region respectively. As
our focus was on the expression of ING1 protein in the
stromal region of breast cancer patients, we used the
expression of ING1 in the vimentin positive region of
normal breast tissue sample as our baseline control
(Fig. 1b top panel). The ING1 localization was found to
be primarily nuclear in these regions with a mean AQUA
score of 109, which was used as a cut point to dichotomize
patients. In breast cancer patient samples, varying levels of
ING1 expression were found in the stromal (vimentin
positive) regions, which were quantified and then used for
classifying patients with low stromal or high stromal ING1
expressing tumors.
Figure 1b middle panel shows a representative image of
a sample with low stromal ING1 expression (AQUA score
25.6) and the bottom panel shows representative images
of a patient sample with high stromal ING1 expression
(AQUA score 291).
Prognostic value of stromal ING1 expression in breast
cancer patients
As described previously, the cohort tested in this study
has patients classified into luminal breast cancer (ER
Fig. 1 Immunohistochemical staining and quantitation of stromal ING1 using the HistoRx AQUA platform. a Representative images showing
specificity of the ING1 monoclonal antibody in HEK293 cells and HEK293 cells overexpressing ING1a (left panels) and in placenta treated with or
without the ING1 antibody (right panels). b Representative examples of quantitative fluorescent IHC images for ING1 expression in normal breast
tissue (top row of panels) and breast cancer tissue (two bottom rows of panels). tAQUA scores represent the expression level of ING1 within the
pan-cytokeratin defined epithelial/tumor compartment; sAQUA scores represent expression level of ING1 in the vimentin defined mesenchymal/
stromal compartment. DAPI-stained nuclei are depicted in blue, pan-cytokeratin stained epithelial/tumor cells are depicted in green, ING1 protein
expression is depicted in red and vimentin stained mesenchymal/stromal cells in white
Thakur et al. Molecular Cancer  (2015) 14:164 Page 3 of 13
positive and Her2 negative, n = 430) and non-luminal
breast cancer (ER negative or Her2 positive, n = 32)
groups for analysis. We tested the prognostic value of
stromal ING1 expression in both populations.
Contrary to the observations made with ING1 expres-
sion in the tumor compartment [31], significant results
were obtained in the luminal group. In this group, stromal
ING1 expression correlated with clinico-pathological char-
acteristics like tumor grade (p = 0.001) and tumor size (p
= 0.020) whereas the non-luminal group did not show cor-
relation to any of the clinic-pathological characteristics
listed in Table 1. High stromal ING1 expression in the
luminal group also correlated to poor survival outcomes
in patients as indicated by Kaplan Meier analysis. This ob-
servation was made in both survival outcomes, including
disease free survival (Fig. 2b, p = 0.0001) and disease spe-
cific overall survival (Fig. 2e, p = 0.0076). Interestingly, no
differences in survival outcomes were seen in this ana-
lysis in the non-luminal group dichotomized by ING1
expression (Fig. 2c and f ) which previously has shown
that higher ING1 expression in the tumor compartment
could predict better survival outcome for breast cancer
patients [31]. This observation suggests that ING1 ex-
pression level in tumor and stromal regions could spe-
cifically predict survival of patients having different
types of breast cancers.
Next, a Cox proportional hazards model was used to
assess the independent prognostic value of stromal ING1
in the cohort. This analysis was performed to determine if
any of the clinically relevant biomarkers along with stro-
mal ING1 levels has a strong prognostic/predictive ability
regarding disease free survival in the cohort. Established
biomarkers such as tumor grade, tumor size, lymph node
status, ER levels and HER2 status were included in the
multivariate model along with stromal ING1 levels, since
these variables are routinely used clinically. The variables
included in the analysis were compared for their hazard
ratio (HR), which indicates the prognostic power of a
given biomarker. In the analysis, tumor grade [HR 2.741,
p = 0.002], lymph node status [HR 3.505, p < 0.001] and
stromal ING1 [HR 2.320, p = 0.002], were significantly and
independently associated with disease free survival in
ER+/HER2- population (Table 2). This suggests that
stromal ING1 levels are equal in predictive power to
the established variables of tumor grade and lymph
node status in the cohort tested in this study.
ING1 regulates levels of cytokines produced in mammary
fibroblasts
In the stroma, fibroblasts are the most abundant cell type
and are the most active cellular component of cancer-
associated stroma [32]. They are believed to play active
roles in the promotion of processes like angiogenesis, me-
tastasis and overall tumor growth through expressing
various paracrine factors [7, 11, 12]. As high stromal ING1
expression significantly correlated with poor patient sur-
vival in the breast cancer cohort tested in this study, we
next determined what cytokines might be regulated by
ING1 in the stroma. For this, ING1a was overexpressed
using adenoviral vectors in the human mammary fibro-
blast cells (HMF3s) and the conditioned media from these
cells was collected and analyzed for various cytokines/che-
mokines using an ELISA based assay. ING1a was chosen,
since it is believed that senescing stromal cells contribute
to the induction of cancers in vivo and we here found that
of the ING1 isoforms, ING1a is most effective in inducing
cellular senescence [22]. Figure 3a shows several cytokines
Table 1 Association of clinico-pathological characteristics of ER+/
HER2- breast cancer patients with levels of ING1 in the stroma
Characteristics # of cases
(%)
ER+/Her2-
Low lng1 High lng1 P-value
Age
< 53 72 (16.25) 56 16 0.880
≥ 53 371 (83.75) 284 87
Menopausal status
Pre-menopausal 26 (5.90) 17 9
Peri-menopausal 21 (4.70) 18 3 0.231
Post-menopausal 321 (72.50) 242 79
n/a (male) 1 (0.20) 1 0
Unknown 74 (16.70) 62 12
Stage
I 188 (42.40) 148 40 0.365
II 138 (31.20) 105 33
III 36 (8.20) 24 12
IV 5 (1.10) 3 2
Unknown 76 (17.20) 60 16
Tumor grade
1 103 (25.40) 88 15 0.001
2 247 (60.80) 195 52
3 56 (13.80) 31 25
Tumor size
< 2 cm 223 (53.86) 179 44 0.020
≥ 2 cm 191 (46.14) 137 54
Lymph node status
Negative 278 (72.77) 220 58 0.103
Positive 104 (27.23) 74 30
Rx Tamoxifen
No 161 (37.44) 118 43 0.196
Yes 269 (62.56) 212 57
The listed clinico-pathological characteristics were analyzed for their correlation
with low/high levels of stromal ING1. Stromal ING1 shows a correlation with
tumor grade and size in the ER+/ Her2- group of patients in the cohort
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that showed a significant decrease in levels upon ING1a
overexpression compared to GFP overexpressing HMF3s
cells. In contrast, some cytokines in the panel were upreg-
ulated upon ING1a overexpression (Fig. 3b), the mechan-
ism of which needs to be further investigated.
Tumor associated stroma is also known to produce a
plethora of matrix metalloproteases (MMPs), which act
on the cell surface of cells and help tumor cells to invade
surrounding tissue and metastasize to distant regions to
form secondary tumors. Taking this into consideration,
we tested for changes in the levels of various MMPs and
their inhibitors, tissue inhibitors of metalloproteases
(TIMPs). There were significant changes in the amount
of all MMPs examined in HMF3s cells overexpressing
ING1a, with simultaneous decrease in the levels of in-
hibitory TIMPs. Figure 4a shows the MMPs and TIMPs,
which show a significant change in levels with respect to
ING1 overexpression in HMF3s cells. With the excep-
tion of MMP-2, all other MMPs increased in levels while
TIMPs decreased in cells overexpressing ING1a, consist-
ent with ING1 playing an active role in invasion and
metastasis.
Functional assay for MMPs regulated by ING1a in HMF3s
cells
Since we saw a significant change in the levels of MMPs
released by HMF3s cells upon ING1a overexpression, our
next question was to determine the functional activity of
the MMPs produced. The activation of MMPs is believed
to be a key feature in inducing tumor invasiveness and
metastasis both in vitro and in vivo and both MMP-1 and
MMP-2 have been identified as genes associated with the
ability of human breast cancer cells to metastasize spon-
taneously to the lungs in immune deficient mice [33]. In
another study involving a mammary fat pad rat xenograft
model, expression of MMP-1 in stromal fibroblasts was
shown to confer high invasion potential to breast carcin-
oma cells [34].
Using zymography analysis, we determined the casei-
nolytic and gelatinolytic activity of MMP-1 and MMP-2
Fig. 2 Kaplan-Meier survival analysis. a-c Kaplan-Meier survival curves for Disease free survival (a) in total population (b) ER+/HER2- group (c) ER- or
HER2+ group. d-f Kaplan-Meier survival curves for Disease specific overall survival (d) in total population (e) ER+/HER2- group (f) ER- or HER2+ group
Table 2 Multivariate analysis of disease free survival
Variable Hazard ratio P value 9 % CI
All patients
Tumor grade 2.741 < 0.001 1.618–4.647
Tumor size 1.431 0.188 0.840–2.437
Lymph node status 3.505 < 0.001 2.142–5.737
ER 0.360 0.010 0.165–0.785
HER2 1.669 0.391 0.518–5.383
Stromal 1NG1 2.125 0.004 1.270–3.557
ER+/HER2-patients
Tumor grade 2.447 0.002 1.374–4.358
Tumor size 1.401 0.236 0.802–2.446
Lymph node status 3.429 <0.001 2.014–5.839
Stromal 1NG1 2.320 0.002 1.356–3.969
Multivariate analysis of clinically relevant biomarkers along with stromal ING1.
Stromal ING1 level is a significant and independent biomarker in the total
population and ER+/HER2- sub-population in the Calgary Tamoxifen Cohort
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Fig. 3 Cytokine profile of HMF3s upon ING1a overexpression. a Cytokines showing decrease in concentration upon ING1a overexpression in
HMF3s cells as compared to GFP control (n = 3; * p < 0.05; ** p < 0.001; *** p < 0.0001). b Cytokines showing increase in concentration upon
ING1a overexpression in HMF3s cells as compared to GFP control (n = 3; ** p < 0.001; *** p < 0.0001)
Fig. 4 MMPs/TIMPs regulated by ING1a in HMF3s cells. a Levels of MMPs and TIMPs upon ING1a overexpression in HMF3s cells (n = 3; ** p < 0.001;
*** p < 0.0001). b Zymographs depicting caseinolytic and gelatinolytic activity of MMP-1 and MMP-2 respectively in HMF3s cells. The bottom panel
shows densitometric analysis of zymographs
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respectively in cells expressing ING1a. Results obtained
from this experiment were in line with the results from
ELISA based analysis as conditioned media from HMF3s
cells overexpressing ING1a had greater MMP-1 activity
compared to media from untreated cells and GFP only
expressing cells (Fig. 4b). Similar to our previous obser-
vations, the activity of pro-MMP-2 was reduced in the
conditioned media from ING1a overexpressing HMF3s
cells in comparison to control and GFP expressing cells.
ING1a overexpressing HMF3s cells induce disorganization
of breast cancer cell derived organoids
In a physiological setting, cancer associated fibroblasts
in the stroma are believed to release factors that help
tumor cells to invade surrounding tissue, metastasize or
divide more rapidly. In order to recapitulate this phy-
siological phenomenon in vitro we employed a three
dimensional culture system in which cells from an ER+
breast cancer cell line MCF7, and HMF3s fibroblast cells
expressing ING1a, were grown separately in the context
of matrix support to provide an environment that more
closely reflects an in vivo setting. We then co-cultured
MCF7 and HMF3s expressing ING1a in order to test
whether paracrine factors released by HMF3s upon
ING1a overexpression could affect organoids formed by
MCF7.
The organoids derived from both MCF7 and HMF3s
cells were monitored at distinct time intervals by phase
contrast microscopy. Non-transformed mammary epi-
thelial cells are known to form spheres with lumens in
three-dimensional cultures, that mimic mammary gland
tissue [35]. We found that both MCF7 as well as control
HMF3s cells expressing GFP formed filled spheres
(Fig. 5a and b) in culture. This observation is expected
with MCF7 being a breast cancer cell line derived from
a metastatic site and the HMF3s fibroblast cell line being
of mesenchymal origin. HMF3s cells overexpressing
ING1a cultured alone also formed filled spheroids which
Fig. 5 Three dimensional co-culture of MCF7 and HMF3s cells. Panel a ING1a induces disorganization of MCF7 breast cancer cell-derived
organoids. MCF7 or HMF3s cells were grown individually or co-cultured in Matrigel in three-dimensional cultures in ultralow attachment 96-well
plates. Representative images of day 14 (a) MCF7 cells alone (b) HMF3s cells expressing GFP (c) HMF3s cells expressing ING1a; inset magnified
spheroid (d) MCF7 cells co-cultured with GFP expressing HMF3s cells (e) MCF7 cells co-cultured with HMF3s cells expressing ING1a captured by
digital camera phase contrast microscopy. Panel b MMP blockade partially reverses ING1a induced morphology changes in MCF7 cells. MCF7
cells were supplemented with conditioned media from HMF3s cells infected with Ad-ING1a or Ad-GFP, alone or in combination with GM6001.
Representative images after 24 h were captured using a phase contrast microscope
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were considerably smaller in size than those formed by
MCF7 and GFP expressing HMF3s cells when cultured
alone (Fig. 5c).
Three dimensional culture assays allow phenotypic
discrimination between nonmalignant and malignant
mammary cells. Nonmalignant cells grown in a three
dimensional context form growth arrested acinus-like
colonies, whereas malignant cells form disorganized
colonies that continue to proliferate [36]. Similar re-
sults were obtained when HMF3s cells overexpressing
ING1a were co-cultured with MCF7 cells (Fig. 5e). The
colonies formed in this combination were more disorga-
nized and distorted as compared to individual controls
and when MCF7 cells were co-cultured with GFP-
expressing HMF3s cells (Fig. 5a, panel d, Additional file 1:
Figure S1).
To test if the aggressive colonies formed were due to
higher amounts of secreted MMPs upon ING1a overex-
pression in HMF3s cells, we next examined the mor-
phology of MCF7 cells supplemented with conditioned
media from HMF3s treated with the broad specificity
MMP inhibitor GM6001. MCF7 cells supplemented with
conditioned media from ING1a expressing HMF3s cells
show a clear change in morphology (Fig. 5b panel b) in
line with our previous observations. This phenotype was
largely reversed when cells were supplemented with
media from ING1a expressing HMF3s cells treated with
GM6001 (Fig. 5b panel e). Cells looked more fusiform
compared to cells treated with ING1a conditioned media
in the absence of the inhibitor.
Taken together, these data suggest that ING1a expres-
sion in mesenchymal fibroblasts induces release of certain
paracrine factors, which further induce epithelial breast
cancer cells to attain a more aggressive phenotype.
Discussion
In this study we investigated the significance of ING1
expression in the stromal region of breast cancer patients
and tested the prognostic/predictive value of stromal
ING1 as a prognostic factor in the Calgary Tamoxifen
Cohort. Prognostic markers are associated with outcomes
independent from therapy whereas, predictive markers
predict outcome in terms of survival of a specific therapy.
Considering the fact that the patients in the cohort studied
were treated with tamoxifen irrespective of the ER status,
ING1 acting as a predictive or prognostic marker remains
unclear. Results show that stromal ING1 correlates with
clinico-pathological characters like tumor grade (p = 0.001)
and tumor size (p = 0.020) in the luminal (ER+/HER2-)
breast cancer group consisting of 443 patients in the
cohort. Specifically, low stromal ING1 expression was asso-
ciated with tumor grade and size, i.e. patients with lower
expression of stromal ING1 had better prognosis. This is
an interesting observation and in contrast to what was
observed in the case of tumor ING1 expression. There-
fore, it appears that high ING1 levels in tumor and low
ING1 levels in stroma predict the best outcomes for
patients.
We also investigated if stromal ING1 expression was as-
sociated with disease free survival and disease specific over-
all survival by analyzing survival outcomes using Kaplan
Meier curves. Significant association with 5 year DFS were
observed in both the luminal group (p = 0.0001) and in the
total population (p = 0.0001) of the cohort, with patients
expressing low stromal ING1 having a better prognosis
than patients with high stromal ING1. Similar results were
obtained when the association with 7 year DSOS was ana-
lyzed, with both the luminal group (p = 0.0076) and total
population (p = 0.110) showing better prognosis than the
low stromal ING1 category, although the relationship was
less statistically significant. Patients from the non-luminal
category were also analyzed for similar associations, but
no significant results were obtained for DFS or DSOS,
suggesting that ING1 expression in different compart-
ments of tissue (tumor/stroma) may have different roles
to play in promoting or inhibiting the development of dif-
ferent sub-types of breast cancers.
Furthermore, multivariate analysis using Cox propor-
tional hazards regression to adjust for important clinical
covariates, confirmed that stromal ING1 expression was
independently associated with DSS in breast cancer.
When taking the total population of the cohort into
account, stromal ING1 (HR 2.125, p = 0.004) not only
came out to be an independent prognostic marker for
breast cancer, but had better predictive power than
already established biomarkers like HER2, ER and tumor
size, which are commonly used in the clinic. When the
luminal only group was analyzed, similar results were
obtained, where stromal ING1 (HR 2.32, p = 0.002) came
out as an independent prognostic marker in the cohort
tested. In this particular population, stromal ING1 had
better predictive value than tumor size, which is a clinic-
ally used biomarker. These results indicate that stromal
ING1 is not only associated with patient survival and
clinico-pathological characters like tumor grade and size
in breast cancer, but could also be developed into a bio-
marker for breast cancer considering its predictive value
than currently used clinical biomarkers. Further testing
needs to be done in this regard by validating the present
observation in a different breast cancer cohort, along
with clinical testing, to establish stromal ING1 as a bona
fide biomarker in breast cancer.
As this observation of association of stromal ING1
with patient survival was unanticipated for a typical
type-II tumor suppressor, we wanted to determine the
underlying reason for association of higher stromal
ING1 expression with poor prognosis of patients in the
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luminal group of the cohort. Tumor cells in a patient
are surrounded by a complex microenvironment that in-
cludes the extracellular matrix, diffusible growth factors
and cytokines, and a variety of non-epithelial cells like
endothelial cells, pericytes, smooth muscle cells, immune
cells and fibroblasts collectively called as stroma. The con-
cept of growth regulatory interactions between the stroma
and adjacent epithelial cell population was first introduced
by Schor et al. [37, 38]. This interaction is mediated by
soluble autocrine/paracrine factors secreted from stromal
cells that induce physiological changes such as increased
proliferation, migration etc. in the adjacent epithelia. Spe-
cifically, fibroblasts present in the stroma are known to
produce several families of growth factors that are key me-
diators of stroma-tumor cell interactions. Since fibroblasts
constitute the majority of the stromal cells within a breast
carcinoma, we used a human mammary fibroblast cell line
to examine changes in cytokines and growth factors
produced by these cells upon modulating levels of ING1.
One previous study reported a role for the ING4 member
of the ING family in regulating the secretory phenotype of
primary fibroblasts [39], which is interesting in light of the
fact that the different ING family members are stoicho-
metric members of both histone deacetylase (HDAC,
INGs 1&2) and histone acetyltransferase (HAT, INGs
3,4,5) complexes, and they appear to have overlapping
function in regulating the secretome.
Since ING1b induced cell death in HMF3s cells, we
used ING1a, which is known to induce senescence [22]
in our experiments to determine the cytokine profile of
these cells. Various studies have provided evidence that
senescent human fibroblasts can promote the proliferation
of pre-malignant and malignant epithelial cells in culture,
and the formation of tumors in mice [32, 40, 41]. This is
likely due to the fact that senescent fibroblasts show a
senescence-associated secretory phenotype (SASP), which
is similar to the paracrine growth factors and cytokines
made in tumors that can contribute to cancer progression.
Contrary to our expectations, our results showed that there
was a significant decrease in the number of pro-
inflammatory and proliferative cytokines such as IL-6, IL-8,
PDGFA, PDGFB, VEGF and GRO in HMF3s cells upon
ING1a overexpression. Chemotactic cytokines promoting
growth and recruitment of immune cells (neutrophils,
monocytes and macrophage) like Eotaxin, Fractalkine and
MCP-3 were also released at lower amounts compared to
controls. However, IL-15 and IP-10 which are known to
have anti-apoptotic and anti-angiogenic properties [42, 43]
also had lower levels upon ING1a expression in HMF3s
cells, suggesting that these pathways may be activated by
senescing fibroblasts.
Apart from the majority of cytokines and chemokines
having reduced levels, some cytokines were increased
upon ING1a expression. An increase in the levels of
immune cell (granulocyte, monocyte and macrophage)
promoting cytokines such as G-CSF, GM-CSF and MIP-1a
was also observed along with increases in chemotactic and
pro-inflammatory cytokine MCP-1.
In contrast to the ING1a effects on cytokines and
chemokines, a much more directed effect was seen for
matrix metalloproteases. Stromal cells secrete matrix
metalloproteases such as MMP-1, 2, 3, 9 and 10, all of
which can promote epithelial transformation [44] and are
known to have pro-angiogenic and metastatic properties
[45, 46]. Previous studies have shown that senescent cells
secrete increased levels of MMPs and the MMP family
members that are consistently upregulated in fibroblasts
undergoing senescence are MMP-1, 3 and 10 [17]. Our
previous study shows that ING1a induces senescence
suggesting that these MMPs may contribute to epithe-
lial cell transformation. Significant increases in the
levels of MMPs implicated in senescence upon ING1a
overexpression in HMF3s cells also indicates senes-
cence induction in these cells. A reciprocal effect was
observed in the case of inhibitors of MMPs (TIMPs) as
the levels of TIMP-2, 3 and 4 showed a significant
decrease in ING1a expressing cells indicating that both
MMP production increased and inhibitor of MMP activity
had decreased in a coordinated manner in these cells.
These results clearly showed an increased amount of
MMPs being secreted by the HMF3s cells expressing
ING1a. To test if the MMPs secreted were active, we per-
formed zymography with specific substrates for MMP-1
and MMP-2 to analyze their enzymatic activity in vitro.
Activities on the zymogram corresponding to levels of
MMP-1 and 2 previously observed were obtained confirm-
ing that the MMPs secreted by ING1a expressing HMF3s
cells were biologically active.
Next, in order to functionally investigate whether
soluble factors produced by fibroblasts upon ING1a
expression are able to induce changes in tumor cells,
we co-cultured HMF3s cells and MCF7 cells and stud-
ied their behavior in three dimensional cultures. The
organoids formed when HMF3s cells expressing ING1a
were co-cultured with MCF7 cells were highly disorga-
nized as compared to GFP expressing co-cultured cells.
This is an indication that the MMPs and cytokines
secreted by ING1a expressing cells were able to induce
morphological changes in the cancer cells resulting in
disorganized and more aggressive colonies. Partial
reversal of morphology of MCF7 cells when supple-
mented with conditioned media from ING1a and MMP
inhibitor treated cells in comparison to MCF7 cells
treated with ING1a only media, further indicates that
MMPs play a role in MCF7 cells attaining a more
aggressive phenotype in response to altered levels of
ING1. The ability of ING1a expressing fibroblasts to
stimulate the invasion of tumor cells into the matrix
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indicated that secreted factors produced by these cells
in response to ING1a expression may be sufficient to
induce invasiveness in these cells. This may explain the
phenomenon believed to occur in tumor-stroma interac-
tions in cancer patients, where senescent cancer associated
fibroblasts release soluble factors which provides an envir-
onment that helps the tumors to grow more aggressively
and to metastasize to form secondary tumors.
Overall, these results from the cytokine and MMP
profiling and the functional assays provide a possible ex-
planation for the poor survival of breast cancer patients
having elevated levels of ING1 in tumor associated
stroma as observed in the AQUA analysis of patients
having luminal types of breast cancer in the cohort we
tested. Both major isoforms of ING1, ING1a and ING1b
have been reported to induce senescence in cells upon
overexpression [22, 47, 48] although ING1b also induces
apoptosis at higher levels while ING1a appears to solely
affect senescence. Therefore, we speculate that increased
levels of ING1 in the stroma may induce senescence
which promotes stromal cells developing a senescence
associated secretory phenotype, releasing paracrine and
cytokine growth factors and MMPs. This would result in
more aggressive tumor formation in such patients lead-
ing to their documented poor survival.
Conclusions
Presently, a high incidence of breast cancer is observed
in women worldwide. This is most likely due to the
availability of widespread screening programs used to
detect breast cancer, which otherwise may never get
diagnosed. There is an inverse relation between the cost
of treatment and patient survival as the breast cancer
progresses to higher grades which makes screening and
diagnosing cancers at earlier stages important, improv-
ing patient survival. Our study here provides substantial
evidence for establishing ING1 as a probable biomarker
for breast cancer. We have shown in this study that
ING1 can specifically predict the survival of patients
with luminal type breast cancer. Specifically, higher
ING1 expression in the stroma leads to poor survival of
patients with luminal type breast cancer due to increase
in MMP production, which may in turn allow cancer
cells to escape and form secondary metastasis. Higher
stromal ING1 also establishes a pro-tumor survival
niche by virtue of the cytokines and chemokines released
by the stromal cells. This phenomenon although anom-
alous to a typical tumor suppressor, defines a unique
role of ING1 in breast cancer pathogenesis. Overall, this
study provides important pre-clinical information that
may be helpful to evaluate the potential usefulness of
the ING family of tumor suppressors in breast cancer
prognosis and treatment.
Material and methods
Cell culture
Immortalized human mammary fibroblasts HMF3s (a
kind gift from Dr. Parmjit Jat) and MCF7 cells were
cultured in H-DMEM (Lonza) supplemented with 10 %
FBS, 0.1 mg/ml streptomycin and 100 U/ml penicillin and
maintained in a humidified atmosphere of 5 % CO2 and
95 % air at 37 °C. Cells were routinely tested for myco-
plasma contamination. For MMP inhibitor assays, HMF3s
cells were treated with 10 μM GM6001 (Millipore) MMP
inhibitor alone or in combination with 15 MOI Ad-ING1a
or Ad-GFP. Media were collected after 48 h and stored at
-80 °C till further use. MCF 7 cells supplemented with
conditioned media from these cells were analyzed for
changes in morphology after 24 h using a Zeiss Axiovert
200 M microscope.
Multiplex assay for cytokine and chemokine screening
Media from transfected/infected cells were collected and
screened for released cytokines and chemokines using an
ELISA based assay (Eve Technologies, Calgary Alberta).
Cells (HMF3s) were inoculated overnight in 6 well dishes
and were infected with Ad-ING1a or Ad-GFP virus at 15
MOI and allowed to grow for 48 h with media changed
12 h post infection. After 48 h, cell media were carefully
collected in sterile centrifuge tubes without disturbing the
cells. The media were then centrifuged at 4 °C for 10 min
at 13,000 rpm. After centrifugation, the media supernatant
were transferred into fresh sterile tubes and stored at
−80 °C unless analyzed immediately.
Three-dimensional cell culture
Three-dimensional culture of HMF3s and MCF7 cells
were performed in ultra-low attachment 96-well plates
(BD Biosciences). HMF3s cells were infected with Ad-
ING1a or Ad-GFP at 15 MOI for 48 h. The plates were
firstly coated with 50 μl of 30 % growth factor reduced
Matrigel (3 mg/ml) (BD Bioscience) in complete medium
(DMEM-containing 10 % FEBS, penicillin, streptomycin
and amphotericin B (Lonza) and were incubated for 1 h in
a CO2 incubator at 37 °C to form a layer. Cell suspensions
of HMF3s and MCF7 cells were then made (100 cells/
50 μl) in 30 % Matrigel and were carefully layered without
formation of bubbles on the solidified layer in the wells.
For co-culture experiments, a 1:1 ratio of HMF3s cells and
MCF7 cells was used. Fresh media were supplemented
every three days and images were taken after 2 weeks
using a Zeiss Axiovert 200 M microscope.
Zymography
To determine the activity of matrix metalloproteases
MMP-1 and MMP-2, gelatin and casein zymography
were performed, respectively. Briefly, HMF3s cells were
grown in 6 well dishes and infected with Ad-ING1a or
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Ad-GFP for 48 h at 15 MOI and the media was centri-
fuged at 4 °C for 10 min at 13,000 rpm. The collected
media supernatants were then mixed with 2X sample
buffer (65.8 mM Tris-HCl pH 6.8, 25 % (w/v) glycerol,
2 % SDS, 0.1 % bromophenol blue) and incubated at
room temperature for 10-15 min. The samples were then
subjected to zymography by resolving on 10 % SDS- poly-
acrylamide gels containing 1 mg/ml porcine skin-derived
gelatin (Sigma) or casein (Sigma). After electrophoresis,
the gels were incubated for 30 min at room temperature
with gentle agitation in renaturation buffer (2.5 % Triton
X-100) to remove SDS. The gels were then incubated in
developing buffer (50 mM Tris-HCl, 0.2 M NaCl, 5 mM
CaCl2 and 0.02 % Brij 35) at 37 °C overnight with gentle
agitation. After incubation in the developing buffer, gels
were stained with 0.5 % (w/v) Coomassie Blue R-250 for
30 min and destained with destaining solution methanol :
acetic acid : water (50:10:40). For casein zymography, gels
were pre-run for 30 min at 100 V before loading samples
to remove excess casein.
Patient cohort and ethics
The Calgary Tamoxifen Cohort which contains a demo-
graphic, clinical and pathology data for 819 breast cancer
patients diagnosed between 1985 and 2000 at the Tom
Baker Cancer Centre in Calgary, Canada was used in this
study. Inclusion and exclusion criteria and detailed de-
scription of the cohort have been described previously
[31]. This study involving the Tamoxifen cohort was
ethically approved (Ethics ID E-17422) by the Conjoint
Health Research Ethics Board (CHREB) at the Univer-
sity of Calgary, Canada.
Fluorescence immunohistochemistry and automated
image acquisition
Fluorescence immunohistochemistry and image acquisi-
tion of the patient samples was performed as described
previously [31]. Briefly, 4 μm thick sections were cut from
the TMA block and after deparaffinization, were rinsed in
ethanol, and rehydrated. Heat-induced epitope retrieval
was performed in a decloaking chamber (Biocare Medical,
Concord, CA, USA), and slides were stained using a Dako
Autostainer. Automated image acquisition was performed
using AQUAnalysis® program as described previously [31].
CAb 5 antibody specific to ING1 that can recognize both
ING1a and ING1b was used for analyzing ING1 levels in
patient samples.
Assessment of ING1 expression
The average intensity of target ING1 signal in the stro-
mal mask was tabulated and used to generate stromal
specific AQUA scores, which reflect the average signal
intensity in the stromal area of the tissue sample. The
ING1 expression score was defined as the mean ING1
AQUA score from triplicate cores for each patient sam-
ple. Patients were dichotomized at the lowest or highest
tertiles of ING1 expression within the entire cohort, to
define Low ING1 and High ING1 categories.
Statistical analysis for patient data
Statistical analyses were performed using Stata 12 (Stata-
Corp LP). For survival analysis, disease free survival (DFS)
which is defined as the time of diagnosis to recurrence,
metastatic disease, or death from breast cancer and dis-
ease specific overall survival (DSOS), which is the time of
diagnosis to death from breast cancer were analyzed. Pa-
tients were censored at the time a patient died from an-
other cause, or the follow-up period ended. Kaplan Meier
survival analysis was performed to estimate the probability
of 5-year DFS or 7-year DSOS. Cox proportional hazards
analyses were conducted to assess the impact of clinical
covariates in multivariate analysis.
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Additional file 1: Figure S1. Quantitation of 3-D culture colony
morphological changes. Colony images from 3-D cultures of HMF3s cells
expressing GFP + MCF7 cells and HMF3s cells expressing ING1a + MCF7
cells were visually scored for their levels of disorganization and
aggressiveness as estimated by divergence from uniformity (** p < 0.001).
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